Amarin Message Board

Dr. Bhatt is very impressive. He is speaking at AdCom, correct?

Will the results of EVAPORATE be included at AdCom or does the embargo take precedence?

Adam Feuerstein mentioned Amgen as an ideal fit for Amarin.

Hardly seems against Amarin now!!

Dr. Bhatt is a smart man.

Scripts for week ending 11/8/19 - More All-Time Highs

It's a certainty that Mineral Oil will be brought up and debated during Adcom.

There are currently 190 sales openings and it sounds like the hiring is progressing. A lot of investors take this movement as the company feeling good about expanded labeling and EVAPORATE trial results.

It is?

Adverse events (AE) occurring in ≥5% of VASCEPA patients and statistically more frequently with VASCEPA than placebo:

• Peripheral edema (6.5% VASCEPA patients versus 5.0% placebo patients)
  • There was no significant difference in the prespecified adjudicated tertiary endpoints of new congestive heart failure which occurred in 4.1% of VASCEPA patients versus 4.3% of placebo patients, or in new heart failure requiring hospitalization, which occurred in 3.4% of VASCEPA and 3.5% of placebo patien…

The Amarin Savings Program is a great deal and a lot of the StockTwits community has shown the pricing with the program, which is as little as $9 for 90 days. They say that pricing is saving patients up to $110 per month, or $330 for a 90-day prescription. That program is when using the Vascepa Savings Card.

I don't think this pricing without the savings card will last that long. Amarin is using it as a strategy to get more patients using the drug and I'm sure the list price will increase over t…

Patent case update & potential settlement "Hmmm"; knows Dr. Nissen is corresponding with FDA & Yee notes Nissen's STRENGTH trial is olive oil placebo (actually corn oil which may have OM6 probs) but FOIA not available, sees AMRN raising guidance to high end

Love to see John Thero picking up more shares before AdCom!

Amarin Corporation PLC's President and CEO just picked up 11,601 shares

John F Thero, Amarin Corporation PLC's President and CEO and a director of the company, recently acquired 11,601 shares of the company. The buys took place at $2.50 per share, on October 28, 2019. Thero now owns 3,092,285 shares of the company. Thero operates out of Bridgewater, NJ.

What are they saying on the IHUB AMRN board about buyout rumors?